Mumbai, Naples, October 09, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of a strategic partnership program aimed at expanding the reach of PrecisionSphere™ – the long-acting injectable (LAI) platform developed by its subsidiary, Nanomi B.V. (Nanomi). PrecisionSphere™ demonstrates efficacy and safety in drug delivery and is ready for commercial use, following the recent United States Food and Drug Administration’s (U.S. FDA)  approval for the first product developed with this platform.

Lupin’s partnership program is designed to foster collaborations with companies looking to extend their product lifecycles, whether in development or already on the market, especially those that could benefit from longer-acting formulations.

“With the validation of PrecisionSphere’s capabilities and our proven track record of executing several key strategic partnerships each year, we are ready to expand patient access to advanced LAI treatments through new global strategic collaborations,” said Dr. Fabrice Egros, President – Corporate Development, Lupin. “Our extensive in-house and successful alliance management capabilities will serve as a strategic advantage, as partners strive to deliver innovative LAI solutions to patients at an accelerated pace.”

Dr. Shahin Fesharaki, Chief Scientific Officer, Lupin, said, “PrecisionSphere™ reflects our commitment to innovation and leverages our regulatory expertise, scalable manufacturing capabilities, and flexible collaboration models to lower entry barriers for developing LAIs. This allows partners to efficiently bring advanced LAIs to market across various therapeutic areas and potentially extend the patent life of their products.”

PrecisionSphere™ addresses key compliance issues that lead pharmaceutical companies to lose millions in revenue and experience failed treatment results. Unlike conventional LAI technologies that produce variable particle sizes, this platform allows pharmaceutical companies to manufacture medicines with consistent particle size, shape, and biological properties, leading to improved injectability. It also enables optimized drug levels—the release of consistent drug concentrations throughout the treatment, ranging from weeks to months.

For patients, reduced injection frequency enhances convenience and may lead to greater compliance and potentially better treatment outcomes. For healthcare professionals, this technology would make it possible to control the delivery of a drug at the optimal therapeutic dose during treatment.

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
To know more about Nanomi, visit www.nanomi.com or follow on LinkedIn https://www.linkedin.com/company/nanomi

For further information or queries, please contact
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com